Researchers at the Institute of oncology research (IOR, affiliated to USI and member of Bios+), in collaboration with researchers from the University of Padova, have made a groundbreaking di...
Can one single antibody catch them all? Scientists discover antibodies that recognise all SARS-CoV-2 variants and also other coronaviruses that cause human disease. The finding opens the d...
The Pfizer Prize Foundation awarded 11 studies and 21 researchers, including Dr Nicolò Pernigoni, Dr Elena Zagato and Professor Arianna Calcinotto of the Oncology Research Institute (IOR) and Dr Ferna...
The Experimental Therapeutics group, directed by Prof. Carlo V. Catapano at the Institute of Oncology Research (IOR, affiliated to USI and member of Bios+), in collaboration with Prof. ...
Cancers arise due to a broad spectrum of mutations and hence have very different genetic makeups. Efforts to develop more targeted or personalized therapies rely on potential vulnerabilities of cancer...
The Sallusto group (ETH IMBB and IRB Bellinzona) published a paper in the European Journal of Immunology providing insights on the relationship of human T follicular helper cells in blood (cTfh cells)...
The BRCA2 gene is mutated in many familial and sporadic breast and ovarian cancers, making it an important cancer suppressor. BRCA2 has been long known to function together with RAD51 in DNA break rep...
Bellinzona, Nov. 17, 2022 – During the Dies Academicus, the University of Fribourg conferred to Prof. Federica Sallusto the title Doctor honoris causa (Dr. h. c.) for her excellence in scientific and ...
Secretory Immunoglobulin A (SIgA) is the antibody produced within mucosal membranes and is the most abundant antibody type synthesized in our body. In the intestine, SIgA possesses two antithetic func...
Melanoma is the most lethal skin cancer, and its incidence, though low, has steadily increased over the last few years. During melanoma progression, tumor cells spread across the body via the lymphati...
The Institute for Research in Biomedicine (IRB) officially opened an international call for the recruitment of a new group leader (deadline December 1, 2022). We seek an outstanding scientist to comp...
Recent years have generated considerable demand for information and interaction between Science and society. In this sense, the open day organized in the new Bios+ building in Bellinzona by IRB, IOR...
On 1 September 2022, a new research group led by Dr Arianna Baggiolini began its activities at the Institute of Oncology Research (IOR) in Bellinzona. This makes six groups in the research programme d...
A study conducted by scientists at the Institute of Oncology Research (IOR, affiliated with USI and a member of Bios+) in collaboration with researchers specialized in veterinary oncology at the Unive...
On Saturday, May 14, the Institute for Research in Biomedicine (IRB), the Institute of Oncology Research (IOR) and the Laboratories for Translational Research of the EOC opened the doors of the new Bi...
The Lymphoma Genomics group, directed by Prof. Francesco Bertoni at the Institute of Oncology Research (IOR, affiliated to USI and member of Bios+), identified a new mechanism behind the resistance to...
The Molecular Oncology research group lead by Prof. Andrea Alimonti at the Istitute of Oncology Research (IOR, affiliated to USI and member of Bios+) has identified, through the use of bioinform...
Lymphomas have always been a main focus for the Institute of Oncology Research (IOR) and the Oncology Institute of Southern Switzerland (IOSI - EOC). After many years dedicated to lymphoma research, B...
The SIB Swiss Institute of Bioinformatics is an internationally recognized non-profit organization dedicated to biological and biomedical data science. It is present in the main academic institutions ...
The EACR European Association for Cancer Research has included a publication of the Institute of Oncology Research (IOR, affiliated to USI) in its "Top 10 Cancer Research Publications", which ranks th...
The awards for the 31st Pfizer Prize for Research were given on Thursday, February 10th, in Zurich. Among the winners of the Oncology category were Ilaria Guccini and Ajinkya Revandka, former research...
The New England Journal of Medicine (NEJM), the world's leading medical journal, has entrusted the lymphoma group of the Institute of Oncological Research (IOR, affiliated to USI and member of Bios+) ...
In the fight against tumours, how the key driver mutations related to disease progression and metastatic spread regulate gene expression to promote ultimately tumor progression and cancer cell adaptat...
Watch the recap video: Watch the complete video recording: ...
The European Molecular Biology Organisation (EMBO) has selected Roger Geiger, group leader at the Institute for Research in Biomedicine (IRB, affiliated to USI Università della Svizzera...
DNA end resection is required for accurate processing of broken DNA. In a paper published in Nature Communications, IRB researchers Acharya, Cejka and colleagues investigated the interplay o...
Swiss Cancer League - Krebsliga - has awarded the 2019 Robert Wenner Prize for young cancer researchers to Davide Rossi, Group leader at the Institute of Oncology Research (IOR, affiliated to Universi...
Oltre 250 le persone presenti alla cerimonia del nuovo stabile di proprietà della Fondazione IRB Si è tenuta oggi la cerimonia d’inaugurazione ufficiale della nuova sede degli Istituti di ricerca s...
On October 22, 2021, the Helmut Horten Foundation celebrated its 50th anniversary with a ceremony held at ETH Zurich. On this occasion, researchersDavide Rossiat the Institute of Oncology Research (IO...
Scientists at the Institute of Oncology Research (IOR, affiliated to USI) and The Institute of Cancer Research, London, in collaboration with researchers from the University of Padova, have made a ver...
A Nature paper by theSystems Immunologygroup, headed byRoger Geiger, at the Institute for Research in Biomedicine (IRB, affiliated to USI). This study describes an innovative strategy to improve the ...
The Swiss National Science Foundation (SNSF) has recently awarded three group leaders at the Institute for Research in Biomedicine (IRB, affiliated to USI): Silvia Monticelli, Santiago González and Pe...
During inflammatory reactions, the production and release of chemotactic factors guide the recruitment of selective leukocyte subpopulations. The chemokine CXCL12 and the alarmin HMGB1, both released ...
Following the development of a second-generation antibody against the novel coronavirus (SARS-CoV-2) and its variants, the Institute for Research in Biomedicine (IRB, affiliated to USI) is now mo...
The American Society of Hematology (ASH) – the world’s leading association in the field of hematology – has awarded Dr. Adalgisa Condoluci, a researcher at the IOR, with the “ASH Global Research Award...
The spillovers of β-coronaviruses in humans and the emergence of SARS-CoV-2 variants highlight the need for broad coronavirus countermeasures. A study co-authored by Dr. Jun Siong Low, Postdoc at t...
Researchers of the Prostate Cancer Biology group, directed by Giuseppina Carbone, M.D. of the Institute of Oncology Research (IOR) discovered an unexpected mechanism that drives the evolution of...
About 10% of the children with alpha1-antitrypsin deficiency must undergo liver transplantation. Their hepatocytes fail to properly degrade polymers of mutant alpha1-antitrypsin (ATZ), whose accumulat...
Systemic light-chain amyloidosis (AL) is the most common form of a group of diseases associated with protein misfolding, leading to deposition of insoluble structures in different organs. Due to the...
A paper from the González’s lab studies how to modify the innate immune response to improve the adaptive immunity against a potential HIV vaccine. To study this mechanism, we have employed the revolu...
The bite of a tick can transmit Tick-Borne Encephalitis Virus (TBEV), which can cause brain infection, hospitalisation and long term neurologic problems. TBEV is only one among half a dozen vir...
Stiftung Experimentelle Biomedizin has awarded Dr Arianna Calcinotto, Group Leader at the Institute of Oncology Research (IOR, affiliated to USI Università della Svizzera italiana) the Peter Hans...
The IRB announces it has joined the United World Antiviral Research Network (UWARN), the organisation that brings together researchers from leading institutions in several countries around the globe t...
A study conducted by the Institute of Oncology Research (IOR, affiliated to USI) based on data obtained from the Veneto Tumor Registry (Italy) has observed a lower risk of developing the coronavirus d...
A given substance may be fundamental for life or may serve as a poison. All depends on the specific dose. At first glance, this somewhat paradoxical principle in medicine was first coined by the Swiss...
The study by Albino et al. is published in Communications Biology and is available at https://doi.org/10.1038/s42003-020-01642-5. The work is a collaborative effort involving many rese...
The Institute for Research in Biomedicine (IRB; Bellinzona, Switzerland), affiliated to the Università della Svizzera italiana (USI) developed a second-generation ‘double antibody’ that protects from ...
While populations around the world are being vaccinated against SARS-CoV-2, the U.S. Food and Drug Administration has announced the approval of a treatment against another well-known virus, much les...
Prof. Alimonti from the Institute of Oncology Research (IOR) in Bellinzona, Switzerland and Prof. De Bono from the Institute of Cancer Research (ICR) in London, United Kingdom, just received this pres...
The so-called “androgen-deprivation” treatments used in prostate cancer therapy may have a protective effect against COVID-19. A study conducted by the Istitute of Oncology Research (IOR, affiliated ...